NCT03861351

Brief Summary

This is a multicenter, non-comparative trial following participants implanted bilaterally with the Mini WELL Toric Ready intraocular lens (IOL) for 6 months after the second eye implant. The objective of the study is to evaluate the clinical performance of the Mini WELL Toric Ready intraocular lens (IOL), in particular, visual performance and rotational stability at 6 months following the second eye implantation in participants suffering from bilateral cataract with corneal astigmatism. There are 2 hypotheses:

  • Rotational Stability: the rotation of the Mini WELL Toric Ready IOL compared between Visit 0a (the day of surgery) and Visit 4 (120 180 days post-operative follow-up) shall be less than ±10° in 90% of the cases.
  • Severe Visual Distortions: the rate of severe visual distortions for the Mini WELL Toric Ready IOL reported at 6 months postoperative will be less than 10 percents.

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
58

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Sep 2019

Typical duration for not_applicable

Geographic Reach
3 countries

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

March 1, 2019

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 4, 2019

Completed
7 months until next milestone

Study Start

First participant enrolled

September 19, 2019

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2021

Completed
Last Updated

April 18, 2023

Status Verified

April 1, 2023

Enrollment Period

2.2 years

First QC Date

March 1, 2019

Last Update Submit

April 14, 2023

Conditions

Keywords

CataractAstigmatism

Outcome Measures

Primary Outcomes (2)

  • Intraocular lens (IOL) rotation

    To evaluate the rotational stability of Mini WELL Toric Ready IOL.

    6 months after second eye implant

  • Rate of severe visual distortions

    To evaluate the visual performance of Mini WELL Toric Ready IOL.

    6 months after second eye implant

Other Outcomes (2)

  • The rate of visual disturbances as detected with the Halometry test

    6 months after second eye implant

  • The rate of secondary surgical interventions (SSIs) related to the optical properties of the IOL for first and second operative eye separately

    6 months after second eye implant

Study Arms (1)

Mini WELL Toric Ready intraocular lens

EXPERIMENTAL
Device: Mini WELL Toric Ready intraocular lens

Interventions

The aim of cataract surgery is to remove the cloudy lens and replace it with the artificial intraocular lens called Mini WELL Toric Ready to correct presbyopia and to correct corneal astigmatism.

Mini WELL Toric Ready intraocular lens

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Eighteen years of age or older at the time of surgery and diagnosed with bilateral cataracts;
  • Planned bilateral cataract removal by phacoemulsification;
  • Preoperative total corneal astigmatism of 0.89 - 2.91 D, measured by corneal topography in both operative eyes;
  • IOL power and cylinder requirement calculated by the specific web-based Mini Toric Calculator within the following range:
  • Cylinder of: 1.50 D to 4.00 D
  • Spherical Equivalent of: 18.00 to 28.00 D
  • Willing and able to complete all required postoperative visits;
  • Clear intraocular media other than cataract;
  • Available for second-eye surgery within 2 weeks of the initial operation;
  • Potential postoperative visual acuity of 0.3 logMAR in both eyes;
  • Able to comprehend and sign a statement of informed consent consistent with local regulation for research in human subjects.

You may not qualify if:

  • Irregular / asymmetric astigmatism;
  • Significant irregular corneal aberration as demonstrated by corneal topography;
  • Keratopathy / Kerectasia - any corneal abnormality, other than regular corneal astigmatism, including, but not limited to the following: keratoconus, keratoglobus, keratolysis, keratomalacia, keratomicosis and corneal plana;
  • Any inflammation or edema (swelling) of the cornea, including but not limited to the following: keratitis, keratoconjuntivitis and keratouveitis;
  • Subjects with diagnosed degenerative visual disorder (e.g. macular degeneration or other retinal disorders) that are predicted (by subjective assessment of the retina) to cause future acuity losses to a level worse than 0.3 logMAR;
  • Subjects who may have reasonably been expected to require a secondary surgical intervention at any time during the study (other than Nd:YAG capsulotomy);
  • Subjects in whom the intraocular lens might interfere with the ability to observe, diagnose or treat posterior segment conditions;
  • Previous corneal refractive surgery;
  • Other planned ocular surgery procedures, including, but not limited to LASIK, astigmatic keratotomy, retinal laser treatment and limbal relaxing incisions, for the duration of the study;
  • Capsular or zonular abnormalities that may affect postoperative centration or tilt of the lens, including but not limited to the following: pseudo-exfoliation syndrome, chronic uveitis, Marfan's Syndrome;
  • Absence of adequate capsular support for the implant of the intraocular lens in the capsular bag;
  • Absence of adequate support for the lens from the posterior chamber or the zonule;
  • Pupil abnormalities, including but not limited to the following: non-reactive, tonic pupils that do not dilatate under mesopic/scotopic conditions, abnormally shaped pupils or abnormally positioned pupils;
  • Amblyopia;
  • Clinically severe corneal dystrophy (e.g. epithelial, stromal, or endothelial dystrophy);
  • +26 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

Service ophtalmologie Segment Antérieur- Hopital Pellegrin - CHU de Bordeaux

Bordeaux, 33076, France

Location

Universitäts-Augenklinik Heidelberg International Vision Correction Research Centre (IVCRC)

Heidelberg, 69120, Germany

Location

OFTALVIST CIO JEREZ Clínica Jerez (Cadiz)

Jerez de la Frontera, 11407, Spain

Location

Hospital Universitario Quirónsalud Madrid

Madrid, 28223, Spain

Location

MeSH Terms

Conditions

CataractAstigmatism

Condition Hierarchy (Ancestors)

Lens DiseasesEye DiseasesRefractive Errors

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Model Details: Men and women aged ≥ 18 years old suffering from bilateral cataract and astigmatism
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 1, 2019

First Posted

March 4, 2019

Study Start

September 19, 2019

Primary Completion

November 30, 2021

Study Completion

November 30, 2021

Last Updated

April 18, 2023

Record last verified: 2023-04

Locations